CONTRAVE (Naltrexon-Bupropion), Drug Insight and Market Forecast – 2032

CONTRAVE (Naltrexon-Bupropion), Drug Insight and Market Forecast – 2032

“CONTRAVE (Naltrexon-Bupropion), Drug Insight and Market Forecast – 2032” report provides comprehensive insights about CONTRAVE (Naltrexon-Bupropion) for Obesity in the 7MM. A detailed picture of the CONTRAVE (Naltrexon-Bupropion) for Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the CONTRAVE (Naltrexon-Bupropion) for Obesity. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CONTRAVE (Naltrexon-Bupropion) market forecast, analysis for Obesity in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Obesity.

Drug Summary

Contrave is a combination of naltrexone, an opioid antagonist, and bupropion, an aminoketone antidepressant, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial Body Mass Index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Contrave has two components: naltrexone, an opioid antagonist, and bupropion, a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system). The exact neurochemical effects of Contrave leading to weight loss are not fully understood.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the CONTRAVE (Naltrexon-Bupropion) description, mechanism of action, dosage and administration, research and development activities in Obesity.

Elaborated details on CONTRAVE (Naltrexon-Bupropion) regulatory milestones and other development activities have been provided in this report.

The report also highlights the CONTRAVE (Naltrexon-Bupropion) research and development activity in Obesity in detail across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around CONTRAVE (Naltrexon-Bupropion).

The report contains forecasted sales of CONTRAVE (Naltrexon-Bupropion) for Obesity till 2032.

Comprehensive coverage of the late-stage emerging therapies for Obesity.

The report also features the SWOT analysis with analyst views for CONTRAVE (Naltrexon-Bupropion) in Obesity.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CONTRAVE (Naltrexon-Bupropion) Analytical Perspective by DelveInsight

In-depth CONTRAVE (Naltrexon-Bupropion) Market Assessment

This report provides a detailed market assessment of CONTRAVE (Naltrexon-Bupropion) in Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

CONTRAVE (Naltrexon-Bupropion) Clinical Assessment

The report provides the clinical trials information of CONTRAVE (Naltrexon-Bupropion) in Obesity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Obesity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CONTRAVE (Naltrexon-Bupropion) dominance.

Other emerging products for Obesity are expected to give tough market competition to CONTRAVE (Naltrexon-Bupropion) and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CONTRAVE (Naltrexon-Bupropion) in Obesity.

Our in-depth analysis of the forecasted sales data of CONTRAVE (Naltrexon-Bupropion) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CONTRAVE (Naltrexon-Bupropion) in Obesity.

Key Questions

What is the product type, route of administration and mechanism of action of CONTRAVE (Naltrexon-Bupropion)?

What is the clinical trial status of the study related to CONTRAVE (Naltrexon-Bupropion) in Obesity and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CONTRAVE (Naltrexon-Bupropion) development?

What are the key designations that have been granted to CONTRAVE (Naltrexon-Bupropion) for Obesity?

What is the forecasted market scenario of CONTRAVE (Naltrexon-Bupropion) for Obesity?

What are the forecasted sales of CONTRAVE (Naltrexon-Bupropion) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Obesity and how are they giving competition to CONTRAVE (Naltrexon-Bupropion) for Obesity?

Which are the late-stage emerging therapies under development for the treatment of Obesity?